HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison
Authors
Keywords
Gastric cancer, Esophageal cancer, Gastroesophageal cancer, Human epidermal growth factor 2 (HER2), Primary tumor location
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 141, Issue 8, Pages 1343-1351
Publisher
Springer Nature
Online
2014-12-27
DOI
10.1007/s00432-014-1900-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer
- (2013) D. Santini et al. ANNALS OF ONCOLOGY
- Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial
- (2013) M. A. Gordon et al. ANNALS OF ONCOLOGY
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
- (2012) Y. Y. Janjigian et al. ANNALS OF ONCOLOGY
- Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
- (2012) V. S. Warneke et al. ANNALS OF ONCOLOGY
- Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer
- (2012) Koen Talsma et al. ANNALS OF SURGICAL ONCOLOGY
- Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
- (2012) H. H. Yoon et al. CLINICAL CANCER RESEARCH
- Adverse Prognostic Impact of Intratumor Heterogeneous HER2 Gene Amplification in Patients With Esophageal Adenocarcinoma
- (2012) Harry H. Yoon et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2/neutesting for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
- (2012) Carlos Gómez-Martin et al. JOURNAL OF CLINICAL PATHOLOGY
- HER2 testing in gastric cancer: a practical approach
- (2012) Josef Rüschoff et al. MODERN PATHOLOGY
- Chromogenicin situhybridization (CISH) to detectHER2gene amplification in breast and gastric cancer: Comparison with immunohistochemistry (IHC) and fluorescencein situhybridization (FISH)
- (2012) Shinichiro Kiyose et al. PATHOLOGY INTERNATIONAL
- Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma
- (2012) Yan Song et al. Chinese Journal of Cancer
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-A systematic review
- (2011) Terence C. Chua et al. INTERNATIONAL JOURNAL OF CANCER
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma
- (2011) Yingchuan Hu et al. MODERN PATHOLOGY
- Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation
- (2011) Rupert Langer et al. MODERN PATHOLOGY
- Comparison Between Established and the Worldwide Esophageal Cancer Collaboration Staging Systems
- (2010) Puja Gaur et al. ANNALS OF THORACIC SURGERY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials
- (2009) I. Chau et al. ANNALS OF ONCOLOGY
- Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance
- (2009) Guan Zhen Yu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females
- (2008) M H Derakhshan et al. GUT
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
- HER-2 overexpression/amplification in Barrett’s oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study
- (2008) Elisa Rossi et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search